Lexicon Pharmaceuticals
LXRX
133 hedge funds and large institutions have $1.1B invested in Lexicon Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 39 increasing their positions, 36 reducing their positions, and 28 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 36
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less funds holding
Funds holding: 137 → 133 (-4)
3.16% less ownership
Funds ownership: 108.74% → 105.58% (-3.2%)
14% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 28
17% less call options, than puts
Call options by funds: $1.11M | Put options by funds: $1.33M
22% less capital invested
Capital invested by funds: $1.41B → $1.1B (-$309M)
Top Buyers
| 1 |
AG
Artal Group
Luxembourg
|
+$7.86M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$6.06M |
| 3 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
+$3.26M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$2.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.53M |
Top Sellers
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$34.5M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$12.1M |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$9.42M |
| 4 |
CCI
Columbus Circle Investors
|
-$5.14M |
| 5 |
BlackRock
New York
|
-$4.94M |
LXRX Hedge Fund Activity: Q4 2017 in Review
133 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2017, worth a combined $1.1B — down 22% from $1.41B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of LXRX and 24 opened new positions — a net loss of 4 holders — while 36 trimmed existing stakes and 39 added.
The largest buyer was Artal Group, adding an estimated $7.86M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $34.5M sold.
- 133 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2017, down from 137 in Q3 2017.
- Funds reported $1.1B of Lexicon Pharmaceuticals stock for Q4 2017, down 22% quarter-over-quarter.
- 24 funds opened new Lexicon Pharmaceuticals positions in Q4 2017 and 28 closed out, a net change of -4 holders.
- The largest Lexicon Pharmaceuticals buyer in Q4 2017 was Artal Group, an estimated $7.86M added.
- The largest Lexicon Pharmaceuticals seller in Q4 2017 was Eagle Asset Management, an estimated $34.5M sold.
Based on aggregated 13F filings for Q4 2017.